{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016285","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.439763+00:00","generated_at":"2026-05-18T22:58:33.946186+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MIRA reports preclinical data for SKNY-1: biased CB1 modulation, CB2 activity, selective MAO-B inhibition","bullets":["SKNY-1 shows biased CB1 antagonism: blocks β-arrestin (cravings) but spares G-protein (mood stability), unlike rimonabant.","Partial agonist at CB2 receptor, targeting metabolic regulation and inflammation for obesity comorbidities.","Selective MAO-B inhibition; no MAO-A or D1/D2/D3 dopamine receptor activity, supporting CNS safety.","Data from Eurofins in vitro studies; in vivo animal models for weight loss and nicotine addiction are being finalized.","Acquisition of SKNY by MIRA remains subject to regulatory and shareholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016285","json":"https://secwatch.observer/filing/0001641172-25-016285.json","markdown":"https://secwatch.observer/filing/0001641172-25-016285.md","text":"https://secwatch.observer/filing/0001641172-25-016285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225016285/0001641172-25-016285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225016285/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:58:33.946186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}